Overview
This real-world prospective study will be conducted to reveal the current status of AndroidAPS use among patients with T1DM in China, evaluate the efficacy of AndroidAPS on glycemic outcomes, and explore the potential factors affecting the time in range(70-180mg/dL) derived from continuous glucose monitoring after AndroidAPS use.
Description
All participants are from TangTangQuan (TTQ; http://www.ttq.so/), the largest online community in China that offers education and support for patients with type 1 diabetes mellitus. Participants are required to sign a written informed consent before enrollment. The healthcare providers of TTQ will help participants build up their own AndroidAPS using a compatible insulin pump, continuous glucose monitoring, and a heuristic-based algorithm on an Android smartphone. All participants will provide their demographic data, diabetic history, current treatment, CGM data, and HbA1c before and after using AndroidAPS.
Eligibility
Inclusion Criteria:
- T1DM was diagnosed by an endocrinologist.
- Currently use AndroidAPS for at least 3 months or plan to start AndroidAPS.
- Willing and able to provide informed consent (or be a parent or other legally authorized representative) and to provide the data.
- reside in China.
Exclusion Criteria:
None